Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $44,000.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $8.80, for a total transaction of $44,000.00. Following the sale, the chief technology officer owned 172,171 shares in the company, valued at $1,515,104.80. The trade was a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Wednesday, August 19th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.20, for a total transaction of $41,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.60, for a total value of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total value of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total value of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Stock Down 1.4%

SOPHiA GENETICS stock traded down $0.12 during mid-day trading on Wednesday, hitting $8.53. The company had a trading volume of 232,020 shares, compared to its average volume of 241,759. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 1 year low of $3.10 and a 1 year high of $8.85. The business has a fifty day moving average of $6.33 and a 200 day moving average of $5.37. The stock has a market cap of $715.58 million, a price-to-earnings ratio of -7.42 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, sell-side analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on SOPH. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. AXQ Capital LP purchased a new position in SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter valued at $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the second quarter valued at $567,000. Royal Bank of Canada boosted its stake in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after acquiring an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in SOPHiA GENETICS during the 1st quarter worth about $1,772,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.